Type Whole antibody Target CA-IX ATC code none | Source Chimeric Trade names Rencarex CAS Number 916138-87-9 | |
Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. It's development was suspended during phase III trials due to efficacy.
Girentuximab was developed by Wilex AG. It was granted fast track status and orphan drug designation by the FDA for renal cancer.
It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.
References
Girentuximab Wikipedia(Text) CC BY-SA